Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | Can we improve on R-CHOP for the frontline treatment of DLBCL?

Georg Lenz • 20 Jun 2019
ICML 2019
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Polatuzumab vedotin
POLARIX

Can we improve on R-CHOP for the treatment of diffuse large B-cell lymphoma (DLBCL)? Georg Lenz, MD, University of Münster, Münster, Germany, discusses this question at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Georg Lenz

1:29
Update from the Lenz lab in Münster
Georg Lenz • 20 Jun 2019
0:55
DLBCL research to watch
Georg Lenz • 20 Jun 2019
0:43
The unmet need in DLBCL
Georg Lenz • 18 Apr 2016
1:08
The importance of recgonizing different DLBCL subtypes
Georg Lenz • 9 Jun 2016

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals